Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary

February 17, 2026

London Stock Exchange GB Health Care Biotechnology earnings 26 min

Earnings Call Speaker Segments

Operator

operator
#1

Hello, and welcome to the conference call covering Palatin's operating results for the second quarter of fiscal year 2026. Right now, everyone is in a listen-only mode. After the formal presentation, there will be a question-and-answer session. Should you need operator assistance at any point during the call, just press star zero on your telephone keypad. Please be aware that this conference call is being recorded. Before we get into our remarks, I want to remind everyone that statements Palatin makes that are not historical facts may constitute forward-looking statements. Such statements rest on assumptions that might or might not turn out to be accurate, and actual results could differ materially from those anticipated because of the various risks and uncertainties covered in the company's most recent filings with the Securities and Exchange Commission. As you evaluate these forward-looking statements about Palatin's prospects, please weigh such risks and uncertainties carefully. I would now like to hand the call over to our host, Dr. Carl Spana, Palatin's President and Chief Executive Officer. Please go ahead.

Carl Spana

executive
#2

Good morning, everyone, and thank you. Palatin's financial results for the second quarter of fiscal year 2026 were reported earlier today, along with a corporate update. Steve Wills, our Chief Financial Officer and Chief Operating Officer, joins me on the call today. We'll highlight today the progress we're making in advancing our obesity pipeline built on the melanocortin 4 receptor, go over recent strategic and financial milestones, and lay out our priorities as we move through 2026, after which we'll open the call for questions. To start, I'll hand the call to Steve for the financial and operating results. Steve.

Steve Wills

executive
#3

Thanks, Carl, and good day to all of you joining us. I'll take you through how operations and financial results came in for the second quarter of fiscal 2026. To begin with the public offering we completed recently: on November 12, 2025, we closed an upsized underwritten public offering of $18.2 million, which included full exercise of the overallotment option. That offering was made up of roughly 2.8 million shares of common stock, or prefunded warrants in lieu of them, together with Series J and Series K warrants, priced at a combined public offering price of $6.50 per share and accompanying warrants. The exercise price on each Series J warrant is $6.50 per share, and it expires on the earlier of 18 months from issuance or 31 days after FDA acceptance of an IND for an in-house obesity treatment compound. As for each Series K warrant, the exercise price is 8.125, $8.125 per share, with a 5-year term, and it is subject to automatic termination in the event the associated Series J warrants are not exercised within the FDA exercise period. We brought in gross proceeds of approximately $18.2 million from the offering, and net proceeds came to approximately $16.9 million after underwriting discounts and offering expenses. The company could receive as much as an additional $18.2 million if the Series J warrants are exercised, though there is no assurance that such exercises will occur.

Steve Wills

executive
#4

The net proceeds from this offering are going toward advancing our obesity programs and also for working capital and general corporate purposes. With this financing closed, Palatin is back in compliance with NYSE American continued listing standards, and as of November 12, 2025, our common stock began trading again on the NYSE American under the ticker PTN. Now I'll move on to the financial results for the second quarter ended December 31, 2025. On revenue, the quarter came in at $116,000, versus zero revenue in the same period a year ago. That revenue is tied to cost reimbursements under our collaboration agreement with Boehringer Ingelheim. Total operating expenses for the quarter were $7.4 million, compared with $2.6 million in the prior year period. The year-over-year comparison is mainly affected by the gain on the sale of Vyleesi booked in the December 31, 2024 quarter, which brought net operating expenses down in that period. In the current quarter, operating expenses rose because of greater investment in our melanocortin-based obesity development programs, along with higher compensation costs and professional fees. Other income, net, was roughly $65,000 for the quarter, versus roughly $169,000 in the prior year period. That decline reflects lower investment income and foreign currency translation gains, partly offset by lower interest expense.

Steve Wills

executive
#5

For the quarter, operations used $4.8 million in net cash, in line with the same quarter a year ago. Our net loss in the second quarter came to $7.3 million, or $2.86 per share, versus a net loss of $2.4 million, or $5.92 per share, for the comparable period a year earlier. That shift reflects increased operating expenses tied to moving our pipeline programs forward, along with the fact that the prior year included a gain from the Vyleesi divestiture that we did not have this time. On cash: as of December 31, 2025, cash and cash equivalents totaled $14.5 million, up from $1.3 million at September 30, 2025, and $2.6 million at June 30, 2025. Under our current operating plans, we anticipate that our cash runway will extend past the quarter ending March 31, 2027. Lastly, regarding the PL9643 sublicensing transaction, in January 2026 we received roughly $3.8 million of upfront consideration through non-cash debt cancellation. That amount appears in current liabilities as of December 31, 2025, and it will be recognized as license revenue in the quarter ending March 31, 2026. To sum up, completing our public offering successfully strengthened our balance sheet considerably, restored our NYSE American listing, and gives us the capital required to move our obesity pipeline ahead while keeping operational flexibility.

Steve Wills

executive
#6

So with that, I’ll hand things back over to Carl so he can walk us through program updates. Carl.

Carl Spana

executive
#7

Thank you, Steve. Palatin keeps carrying out its plan to move forward differentiated therapeutics built on the melanocortin 4 receptor, concentrating chiefly on uncommon syndromic and genetic forms of obesity. In the quarter, we achieved substantial headway in pushing our main obesity programs nearer to the clinic, bolstered our balance sheet, and, as Steve noted, refined our strategic emphasis by sublicensing PL9643, our clinical candidate for dry eye disease. Now looking at the obesity pipeline, we are moving ahead a portfolio of proprietary melanocortin 4 receptor agonists, at first aimed at uncommon neuroendocrine obesity disorders, such as hypothalamic obesity and Prader-Willi syndrome, where medical need remains significantly unmet. Our leading oral small molecule MC4R agonist, PL7737, keeps advancing through IND-enabling toxicology studies, and we stay on schedule to file an IND and begin a Phase 1 single and multiple ascending dose clinical trial during the first half of calendar year 2026. At the same time, we are progressing our next-generation selective melanocortin 4 receptor peptide agonists, which are built for once-weekly subcutaneous dosing. For that program, an IND submission is planned in the second half of calendar 2026. As these programs move ahead, our development efforts center on delivering differentiated product profiles. To be specific, we are engineering our compounds to improve patient tolerability, including the possibility of fewer gastrointestinal side effects, while limiting off-target effects like hyperpigmentation—factors we consider important for success in treating chronic obesity indications over the long term.

Carl Spana

executive
#8

Preclinical results give us reason to believe that hitting melanocortin 4 receptor could work across rare obesity indications as well as certain broader ones. That said, rare neuroendocrine disorders are where we'll concentrate. The registration trials we have planned will take in patients who have hypothalamic obesity and Prader-Willi syndrome. Beyond that, data from preclinical work and early clinical testing back the possibility of giving our melanocortin 4 receptor agonists together with GLP-1-based therapies like tirzepatide, which gives us options as obesity treatment paradigms keep shifting. A couple of other items from the quarter, which Steve mentioned: in January 2026, we sublicensed PL9643 — a selective melanocortin 1 receptor agonist with positive Phase 3 clinical data in dry eye disease — to Altanis Pharma Labs. That deal brought us roughly $3.8 million in upfront consideration and lets us sharpen our focus on our core obesity programs while we keep potential future financial participation through milestones and royalties. We also significantly strengthened our balance sheet by completing an $18.2 million public offering in November, which included the full exercise of the overallotment. In addition, we successfully regained compliance with the New York Stock Exchange American listing standards, and our common stock resumed trading under the symbol PTN, restoring market visibility and liquidity.

Carl Spana

executive
#9

To wrap up, Palatin is heading into 2026 with a stronger financial footing, several partnerships that carry near-term milestones, and a tightly focused, differentiated obesity pipeline. In our view, this puts the company in position to go after meaningful long-term value creation. With that, I'll hand the call back to the operator, and we'll open things up for questions.

Operator

operator
#10

Absolutely. We'll now move into a question-and-answer session. Should you wish to pose a question, please press star one on your phone's keypad. A confirmation tone will signal that your line has joined the question queue. If you'd prefer to withdraw your question from the queue, you can press star two. Those of you on speaker equipment might need to lift your handset before pressing the star keys. Please hold for a moment while we poll for questions. Today's first question comes from Scott Henry of Alliance Global Partners.

Scott Henry

analyst
#11

Thanks. Morning, everyone — we've made quite a bit of progress lately. Maybe we begin with PL7737: as we prepare for the IND, which preclinical or translational signals give you the most confidence that it's differentiated from current or emerging MC4R agonists, especially when it comes to tolerability? Thanks.

Carl Spana

executive
#12

Hi Scott. Let's discuss hyperpigmentation. It's built to target the melanocortin 4 receptor with greater selectivity than the melanocortin 1 receptor, and that ought to produce a decrease — or a substantial decrease — in hyperpigmentation, which addresses the first portion of your question. Look, we manage possible GI side effects via several mechanisms, and one of the most important is how the product gets administered and absorbed. Absorption is slowed so that we avoid fairly large spikes in uptake, since those can cause heightened or stronger GI side effects.

Scott Henry

analyst
#13

Okay, so once we move into the Phase 1 SAD/MAD trial, how are you approaching the choice of patients, and which endpoints ought we to keep in mind regarding what the early clinical data can yield? Also, I saw Prader-Willi — is that getting more attention alongside HO, or does it just look that way because I'm noticing it more prominently than before? Thanks.

Carl Spana

executive
#14

Okay, a few points. For the single ascending and multiple ascending dose studies, those are mainly safety studies. For the single ascending dose in particular, we're really just looking to confirm oral bioavailability, that the product is safe, and to define a dosing window for 7737. We think the same will hold for the long-acting peptide when that moves forward as well. In the multiple ascending dose study, those will run for a longer period. Again, these will be in healthy obese patients. And there, of course, safety is always paramount over the primary efficacy or primary result you're seeking in these kinds of studies. That said, since these will be healthy obese patients, in the MAD portion we'll be looking for a reduction in body weight. We'll be looking for reductions in hyperphagia and control of it, along with other parameters that accompany the obesity indication or controlling the obesity indication. We do expect that we'll get, at least from the MAD portion, a pretty clear signal on how well these compounds can work. What's nice about that is we've seen in our hands that there's very good translatability from smaller studies, smaller efficacy studies, to larger studies with this mechanism.

Scott Henry

analyst
#15

Okay, great. And when it comes to Prader-Willi syndrome, are you putting more focus on that now, or has it always been somewhat in the background?

Carl Spana

executive
#16

It's always sort of been there underneath. Look, we're on the lookout for signals where, naturally, you satisfy the rare and orphan criteria, yet substantial patient numbers exist. When we consider certain of the more micro-orphan conditions rooted genetically in the leptin-melanocortin pathway, patient counts there are comparatively modest. Naturally, those do constitute legitimate markets and legitimate development opportunities. Even so, we continue to examine some of the bigger indications, such as HO and Prader-Willi, where patient populations are considerably larger.

Scott Henry

analyst
#17

Okay, so a final question about the clinical side. Given the oral small molecule plus the once-weekly injection, how do you see those two products being positioned, with one oral and one injectable? Do you think of them as complementary? I'm just trying to understand where we ought to be thinking about each of them.

Carl Spana

executive
#18

I do think of them as complementary, yes. Every one of them will have patient groups for which it fits better. Naturally, for the weekly injectable peptide, you'd anticipate a greater degree of efficacy for those patients—and broadly speaking, we tend to observe across the board that peptides let us achieve better efficacy than small molecules do. That said, we obviously still need to see—the ultimate calls on that are going to hinge on what the early studies show us. There will be patient populations for each. These indications are long-term; they aren't like generalized obesity, where patients can hit a target goal—meaning they can lose a certain amount of weight, get to a healthier place, and then want to shift to lower dosing or maintenance. With these patients, they're likely going to require long-term, fairly aggressive therapy, because fundamentally their conditions are chronic and, in that sense, they don't go away. You're going to need both sets of options to truly manage these patients.

Scott Henry

analyst
#19

Alright. Thanks, Carl. I suppose I’ll let Steve make a few remarks here. Steve, on Q2 OpEx — fiscal Q2 — it appears to be roughly $7.4 million. Did the transaction introduce any sort of one-time noise into that figure? I’m merely attempting to understand how we ought to view that OpEx figure for the March quarter, the fiscal third quarter. Thank you.

Steve Wills

executive
#20

Thanks, Scott. In the fourth quarter of '26, we had several—I'm not sure whether to call them extraordinary or one-time, but I think that's the best way to describe them—and those totaled more than $2 million in that quarter alone, which we don't expect to recur. They were one-time items tied to cleaning up a number of things we couldn't clean up before the raise. As we mentioned in the Q filed earlier today, there were a number of what you might call one-time extraordinary-type expenses that we won't see going forward. I'd target roughly $2.5 million less in the first quarter of '26 and the second quarter of '26 compared with the fourth quarter of 2025, which came in a little over seven—I think approximately $7.4 million.

Scott Henry

analyst
#21

Great. That's exactly right. Thanks for the extra detail, Steve. Thanks to both of you for taking the questions.

Steve Wills

executive
#22

Thanks.

Operator

operator
#23

Today's next question comes from Yale Jen at Laidlaw & Company.

Yale Jen

analyst
#24

Morning, and thank you for taking the questions. I’ll just build a little on what Henry asked. First, on the safety side, as we know, in Prader-Willi syndrome the currently approved drug has some safety concerns, and 15% to 20% of treated patients discontinue. How would you assess that issue when you begin your Phase 1 study and perhaps further down the line?

Carl Spana

executive
#25

During the Phase 1 trial, we will gain a really clear picture of the tolerability as well as the safety profile for each of the two approaches. Drawing on what we've learned with the melanocortin 4 receptor system, we have a fairly solid sense of what should show up. Typically, some GI side effects will appear. Our view is that these can be managed by how such agents are given, so that they occur at lower rates. With this mechanism, we generally don't observe those kinds of discontinuations. As for the GI side effects, they usually tend to run fairly low. Beyond that, we know we want to steer clear of that MCR1 as much as we can, which lets us cut down the potential for hyperpigmentation, something many patients dislike. On the whole, I believe mechanistically this approach will likely lead to fewer discontinuations in these patient populations, while also delivering really strong efficacy. That said, however, you have to get into the clinic, and we have to demonstrate it.

Yale Jen

analyst
#26

Okay, so perhaps a couple of fast questions. First, regarding PWS, you were seeking the hyperphagia signal, and in your Phase 1 trial — though probably more likely in the Phase 2 trial — how do you evaluate those two kinds of measures in the design of your study: one being hyperphagia and the other being weight reduction, so that you can see a clear, hopefully clear, indication that an effect will appear on both fronts?

Carl Spana

executive
#27

Sure. The way we see it is that when we refer to Phase 1, we’re really referring to the multiple ascending dose study. Obviously, from a single dose in healthy normals, we don’t expect to see very much beyond safety.

Yale Jen

analyst
#28

Okay.

Carl Spana

executive
#29

With something like a 14 4-week study — a 28-day trial in healthy obese patients — the thing you're watching for is whether we're seeing consistent target engagement across all 4 weeks of dosing, and whether PK parameters and drug exposure stay consistent. We anticipate that; we know from other studies we've run that we'd expect a drop in food intake and a drop in body mass among these patients. Going more mechanistic: one way the melanocortin 4 receptor operates is that a downstream effect, naturally, is control of hyperphagia, which can show up in obese patients — an obese patient, whether normal or with syndromic obesity like PWS. Until you get into the PWS patients, you won't truly know how much of the hyperphagia you're controlling, correct?

Yale Jen

analyst
#30

Okay.

Carl Spana

executive
#31

But the Phase 1 gives you a really clear signal about whether you’re hitting the target, how much efficacy you’re able to generate, and that ought to carry over into a robust signal in the PWS patients too. Before you reach that point, though, you won’t have the answer. You really do need to get into the actual intended patient population itself.

Yale Jen

analyst
#32

All right. Perhaps we should just keep going with this one — is it the case that, given the resources or the resources you expect down the road, PWS is something you might consider pursuing more aggressively next year, either later this year or really in the next year?

Carl Spana

executive
#33

You're right about that—it's more in the following year. But I'll hand it over to Steve to walk through how cash flow plays out across the next 18 months.

Steve Wills

executive
#34

Thanks, Carl. As Carl said, those SAD/MAD Phase 1 studies are the initial ones, and we are aiming at them—and right now we have enough cash on hand to advance both the oral small molecule and the long-acting peptide, again, into Phase 1 SAD/MAD. Readout of that data will come for the oral small molecule by year-end, and during the first half of next year for the long-acting peptide. After that, we will be moving ahead into what you could call a Phase 2 or a Phase 2/3—specifically in just HO patients and PW, Prader-Willi syndrome, patients—for both the oral small molecule and the long-acting peptide. Those will not begin before mid of 2027. Does that help?

Yale Jen

analyst
#35

Great. Yes, absolutely. That really is great color. Perhaps the final question here is that you have a study combining GLP-1 beforehands. I understand that obviously this is a very, very crowded space, and already a highly competitive space. Certainly you have some positive data — how would you position it, or in what context do you anticipate that GLP-1 may play a role in your product development or clinical study going forward? Thanks.

Carl Spana

executive
#36

Look, I'd say this has been a drawn-out process. We've spent a considerable stretch of time working on pairing these two mechanisms, and as you mentioned, we've run clinical trials that specifically examine how they interact. With more and more incretin-based therapies entering the market — and they're shifting now from injectable forms to oral ones — clinicians will probably want to pair these mechanisms, especially for patients with PWS, for instance, who may have truly very severe hyperphagia and need something beyond what any single mechanism alone can offer. That's the reason we started considering ways to pair these mechanisms so that each patient who comes through can truly receive an optimized therapy. Still, I think it would be somewhat naive to assume that during a clinical development program you'll concentrate on a monotherapy approach — certainly a portion of the patients enrolling in these studies will be taking GLP-1s — but over the longer term, combination therapy is likely to become common. It's really about positioning ourselves for what you might call lifecycle management, or the reality of what will happen in the marketplace once these products secure approval.

Yale Jen

analyst
#37

Thank you. I appreciate that. Congratulations again on having enough resources to keep moving ahead. This is definitely a strong space to be in, and congratulations on everything you've accomplished.

Operator

operator
#38

That brings the Q&A portion to a close, and now I'll hand things over to Dr. Carl Spana, who will offer some closing remarks.

Carl Spana

executive
#39

Thanks. I want to thank all of you for joining the Palatin second quarter fiscal 2026 conference call. We're excited about what we're doing here. I think we're in a very good place with really good assets, and we'll continue to be excited moving these products forward and really updating you as we continue to make progress in our development. That being said, have a great day, and we look forward to continue to update you on our progress. Thank you.

Operator

operator
#40

That brings us to the end of today's call, and you're welcome to hang up your lines now. We appreciate everyone for joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.